IP Library Patent Application 13179785
Patent Application
App. No. 13/179,785

RNA INTERFERENCE MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/179,785
Abstract

This invention relates to compounds, compositions, and methods useful for modulating human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of human immunodeficiency virus (HIV) gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of HIV genes. The small nucleic acid molecules are useful in the treatment of HIV infection, AIDS, and/or diseases and conditions related to HIV infection and/or AIDS in a subject or organism.

Claims (8)

1 . A chemically modified double stranded nucleic acid molecule that mediates RNA interference (RNAi) against a target HIV RNA sequence, wherein:

a) the nucleic acid molecule comprises a sense strand and a separate antisense strand;

b) each strand of the nucleic acid molecule is independently 18 to 24 nucleotides in length;

c) the antisense strand is complementary to the target HIV RNA sequence;

d) a plurality of pyrimidine nucleotides in both the sense strand and the antisense strand are 2′-deoxy-2′-fluoro pyrimidine nucleotides, a plurality of purine nucleotides in the sense strand are ribonucleotides, and a plurality of purine nucleotides in the antisense strand are 2′-O-methyl purine nucleotides.

2 . The nucleic acid molecule of claim 1 , wherein one or more of the chemically modified nucleotides are phosphorothioate linked nucleotides.

3 . The nucleic acid molecule of claim 1 , further comprising inverted deoxy abasic modifications at the 3′-end, the 5′-end, or both the 3′- and 5′-ends of the sense strand.

4 . The nucleic acid molecule of claim 1 , wherein the sense strand comprises a 3′-overhang of 1-4 nucleotides.

Assignments (3)
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2011
From: BEIGELMAN, LEONID; MCSWIGGEN, JAMES
To: MERCK SHARP & DOHME CORP.
Reel/Frame 026574/0051 →